Recharter for Advisory Council on Blood Stem Cell Transplantation, 10905-10906 [2023-03604]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 35 / Wednesday, February 22, 2023 / Notices
The meeting is being amended to
change the meeting date and should
read as follows:
Date: April 21, 2023.
Time: 10 a.m.–6 p.m., EDT.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Natalie Brown, M.P.H., Scientific
Review Officer, National Center for
Chronic Disease Prevention and Health
Promotion, CDC, 4770 Buford Highway,
Mailstop S107–8, Atlanta, Georgia
30341–3717; Telephone: (404) 639–
4601; Email: NBrown3@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–03568 Filed 2–21–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
lotter on DSK11XQN23PROD with NOTICES1
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–CE23–
004: Research Grants for Preventing
Violence and Violence Related Injury;
Amended Notice of Closed Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—RFA–
CE23–004: Research Grants for
Preventing Violence and Violence
Related Injury; March 28–29, 2023, 8:30
a.m.–5:30 p.m., EDT, Videoconference,
in the original FRN. The meeting was
published in the Federal Register on
January 20, 2023, Volume 88, Number
13, page 3743.
The meeting is being amended to
remove the second day and should read
as follows:
Date: March 29, 2023
Time: 8:30 a.m.–5:00 p.m. (EDT)
Place: Videoconference.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Aisha L. Wilkes, M.P.H., Scientific
Review Officer, National Center for
19:42 Feb 21, 2023
Jkt 259001
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
1905 Willowdale Road, Morgantown,
West Virginia 26506; Telephone: (304)
285–5951; Email: MGoldcamp@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–03567 Filed 2–21–23; 8:45 am]
BILLING CODE 4163–18–P
[FR Doc. 2023–03565 Filed 2–21–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
BILLING CODE 4163–18–P
VerDate Sep<11>2014
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341,
Telephone: (404) 639–6473; Email:
AWilkes@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
10905
Frm 00037
Fmt 4703
Sfmt 4703
Recharter for Advisory Council on
Blood Stem Cell Transplantation
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA OH–23–004, NIOSH Miner Safety
and Health Program—Western Mining
States Review; and RFA OH–23–005,
NIOSH Robotic Mining Review.
Date: May 25, 2023.
Time: 1 p.m.–5 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Michael Goldcamp, Ph.D., Scientific
Review Officer, Office of Extramural
Programs, National Institute for
Occupational Safety and Health, CDC,
PO 00000
Health Resources and Services
Administration
In accordance with the
Federal Advisory Committee Act
(FACA), the Department of Health and
Human Services is hereby giving notice
that the Advisory Council on Blood
Stem Cell Transplantation (ACBSCT)
has been rechartered. The effective date
of the recharter is February 19, 2023.
FOR FURTHER INFORMATION CONTACT:
Shelley Tims Grant (Designated Federal
Officer); HRSA Division of
Transplantation, HRSA, 5600 Fishers
Lane, 08W67, Rockville, Maryland
20857; 301–443–8036; or sgrant@
hrsa.gov.
SUPPLEMENTARY INFORMATION: The
ACBSCT advises, assists, consults with,
and makes recommendations to the
Secretary of Health and Human
Services, acting through the HRSA
Administrator, on matters related to the
activities of the C.W. Bill Young Cell
Transplantation Program and National
Cord Blood Inventory and other matters
of significance concerning the activities
under section 379 of the Public Health
Service Act (42 U.S.C. 274k).
The ACBSCT shall provide a
consolidated, comprehensive source of
expert, unbiased analysis, and
recommendations to the Secretary of
Health and Human Services on the
latest advances in the science of blood
SUMMARY:
E:\FR\FM\22FEN1.SGM
22FEN1
10906
Federal Register / Vol. 88, No. 35 / Wednesday, February 22, 2023 / Notices
stem cell transplantation and donation.
The ACBSCT may also review the state
of the science using adult stem cells and
birthing tissues to develop new types of
therapies for patients, for the purpose of
considering the potential inclusion of
such new types of therapies in the C.W.
Bill Young Cell Transplantation
Program.
The recharter for ACBSCT was
approved on February 15, 2023.
Recharter of the ACBSCT charter gives
authorization for the ACBSCT to operate
until February 19, 2025.
A copy of the ACBSCT charter is
available on the ACBSCT website at
https://bloodstemcell.hrsa.gov/about/
advisory-council. A copy of the charter
can also be obtained by accessing the
FACA database that is maintained by
the Committee Management Secretariat
under the General Services
Administration. The website address for
the FACA database is https://
www.facadatabase.gov/.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023–03604 Filed 2–21–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
lotter on DSK11XQN23PROD with NOTICES1
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, PAR–
19–367: Maximizing Investigators’
Research Award, February 23–24, 2023,
10:00 a.m. to 8:00 p.m., National
Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting), which was published
in the Federal Register on January 31,
2023, 88 FR 6288, Doc 2023–01953.
This meeting is being amended to
change the panel name to ‘‘PAR–20–
117: Maximizing Investigators’ Research
Award for Early-Stage Investigators’’.
The meeting is closed to the public.
Dated: February 15, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03572 Filed 2–21–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:42 Feb 21, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Healthcare
Inequities in ADRD.
Date: March 14, 2023.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Sandhya Sanghi, Ph.D.,
Scientific Review Officer, National Institutes
of Health, National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
(2N230) NIA/SRB, Bethesda, MD 20892,
(301) 496–2879, sandhya.sanghi@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: February 15, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03645 Filed 2–21–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health
and Health Disparities; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; John Lewis NIMHD
Research Endowment Program.
Date: March 22, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIMHD DEM II, Suite 800, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Xinli Nan, M.D., Ph.D.,
Scientific Review Officer, Office of
Extramural Research Activities, National
Institute on Minority Health and Health
Disparities, National Institutes of Health,
6707 Democracy Boulevard, Suite 800,
Bethesda, MD 20892, (301) 594–7784,
Xinli.Nan@nih.gov.
Dated: February 15, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03571 Filed 2–21–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Maryann Puglielli at (240)–627–3723, or
maryann.puglielli@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301–496–
SUMMARY:
E:\FR\FM\22FEN1.SGM
22FEN1
]]>Agencies
[Federal Register Volume 88, Number 35 (Wednesday, February 22, 2023)]
[Notices]
[Pages 10905-10906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-03604]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Recharter for Advisory Council on Blood Stem Cell Transplantation
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act (FACA),
the Department of Health and Human Services is hereby giving notice
that the Advisory Council on Blood Stem Cell Transplantation (ACBSCT)
has been rechartered. The effective date of the recharter is February
19, 2023.
FOR FURTHER INFORMATION CONTACT: Shelley Tims Grant (Designated Federal
Officer); HRSA Division of Transplantation, HRSA, 5600 Fishers Lane,
08W67, Rockville, Maryland 20857; 301-443-8036; or [email protected].
SUPPLEMENTARY INFORMATION: The ACBSCT advises, assists, consults with,
and makes recommendations to the Secretary of Health and Human
Services, acting through the HRSA Administrator, on matters related to
the activities of the C.W. Bill Young Cell Transplantation Program and
National Cord Blood Inventory and other matters of significance
concerning the activities under section 379 of the Public Health
Service Act (42 U.S.C. 274k).
The ACBSCT shall provide a consolidated, comprehensive source of
expert, unbiased analysis, and recommendations to the Secretary of
Health and Human Services on the latest advances in the science of
blood
[[Page 10906]]
stem cell transplantation and donation. The ACBSCT may also review the
state of the science using adult stem cells and birthing tissues to
develop new types of therapies for patients, for the purpose of
considering the potential inclusion of such new types of therapies in
the C.W. Bill Young Cell Transplantation Program.
The recharter for ACBSCT was approved on February 15, 2023.
Recharter of the ACBSCT charter gives authorization for the ACBSCT to
operate until February 19, 2025.
A copy of the ACBSCT charter is available on the ACBSCT website at
https://bloodstemcell.hrsa.gov/about/advisory-council. A copy of the
charter can also be obtained by accessing the FACA database that is
maintained by the Committee Management Secretariat under the General
Services Administration. The website address for the FACA database is
https://www.facadatabase.gov/.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023-03604 Filed 2-21-23; 8:45 am]
BILLING CODE 4165-15-P
